By Sabela Ojea


Nurix Therapeutics said the Food and Drug Administration has lifted the partial clinic hold on the U.S. Phase 1A/1B study for NX-2127, evaluated in adults with relapsed/refractory B-cell malignancies.

The clinical-stage biopharmaceutical company's update comes about four months after the company announced the partial clinical hold due to its intention to transition to an improved manufacturing process.

The resolution of the partial hold allows the company to reinitiate enrollment in the NX-2127 Phase 1 study using drug products from its new manufacturing process, said Paula O'Connor, head of clinical development at Nurix.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

03-11-24 0745ET